Eisai Co., Ltd.｜A human health care company

Certificate of Appreciation from National Department of Health of Papua New Guinea

Eisai's Support towards COVID-19
Eisai's Statement of Commitment for Carbon Neutrality by 2040

Medium- to long-term goals to achieve carbon neutrality
Video Library

Videos of Eisai's Activities Including Initiatives for Improving Access to Medicines
Lymphatic Filariasis Elimination Activities in Kenya

Support for MDA and Provision of Water Tanks

News Release
Latest News
Information

December 6, 2021

EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 44TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
November 30, 2021

EISAI AND FCNT ENTER INTO BUSINESS ALLIANCE AIMING TO SUPPORT PEOPLE LIVING WITH DEMENTIA AND TO PREVENT DEMENTIA
Developing solutions such as smartphones equipped with the brain health check tool “NouKNOW®”
November 30, 2021

EISAI TO PRESENT LATEST DATA ON PERAMPANEL AND E2730 AT THE 75TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
November 29, 2021

European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma
First Combination of Tyrosine Kinase Inhibitor with Immunotherapy Approved in Europe for Adult Patients With Advanced or Recurrent Endometrial Carcinoma With Disease Progression on or Following Prior Treatment With a Platinum-Containing Therapy in Any Setting and Who Are Not Candidates for Curative Surgery or Radiation

Approval Based on Study 309/KEYNOTE-775 Results Demonstrating Statistically Significant Improvements in Overall Survival and Progression-Free Survival Compared With Chemotherapy
November 29, 2021

European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Approval Based on Results From CLEAR/KEYNOTE-581 Trial Demonstrating LENVIMA Plus KEYTRUDA Significantly Reduced the Risk of Disease Progression or Death by 61%, With a Median Progression-Free Survival of Nearly Two Years Versus Nine Months for Sunitinib

November 12, 2021

IR "CTAD：Assessment of the Clinical Effects of Lecanemab, the Correlation of Plasma Aβ 42/40 Ratio with Changes in Brain Amyloid PET SUVr, and Safety from the Core and OLE of the Phase 2 POC Study, in Subjects with Early AD"
November 2, 2021

IR “Second Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2022 [Material, Webcast]”
November 1, 2021

IR “Second Quarter Financial Report for the Fiscal Year Ending March 31, 2022”
September 22, 2021

EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY
September 22, 2021

IR “Value Creation Report 2021”

November 24, 2021

Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease
September 22, 2021

EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY
April 19, 2021

Eisai formulates the action plan “Diversity & Inclusion 2021”
December 10, 2020

Notice of Emergence of Employees Infected with the Novel Coronavirus at the Bogor Plant in Indonesia
December 3, 2020

EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT FIFTH ANNUAL WELFARE INDEX PMI* IN ITALY

Eisai at a Glance

Eisai Group Worldwide

About Eisai

About Eisai TOP

Our pursuit of human health care (hhc)

Eisai's hhc Philosophy

Eisai's hhc Philosophy TOP

Investors

Sustainability

Making our medicines available to those who need them

28 countries 2.02 billion tablets

Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of August 2021)

Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries

Sustainability TOP